Comparison of the Solubility and Dissolution Rate Between Gliclazide Solid Complex and Its Nanospheres

REFERENCES

• Aggarwal S., Singh P. N., Mishra B. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin- hydroxypropylmethylcellulose complexes. Pharmazie 2002; 57: 191–193
   PubMed Web of Science ®Google Scholar
• Ammar H. O., Ghorab M., El-Nahhas S. A., Emara L. H., Makram T. S. Inclusion complexation of furosemide in cyclodextrins. Pharmazie 1999; 54: 142–144
   Web of Science ®Google Scholar
• Andersen F. A., Bundgaard H. Inclusion complexation of metronidazole benzoate with β-cyclodextrin and its depression of anhydrate-hydrate transition in aqueous suspensions. Int. J. Pharm. 1984; 19: 189–197
   Web of Science ®Google Scholar
• Bekers O., Uijtendaal E. V., Beijnen J. H., Bult A., Underberg W. J. M. Cyclodextrins in pharmaceutical field. Drug Dev. Ind. Pharm. 1991; 17: 1503–1549
   Web of Science ®Google Scholar
• Blanco J., Vila-Jato J. L., Otero F., Anguiano S. Influence of method of preparation on inclusion complexes of naproxen with different cyclodextrins. Drug Dev. Ind. Pharm. 1991; 17: 943–945
   Web of Science ®Google Scholar
• Bodmeier R., Chen H. Indomethacin polymeric nanosuspensions prepared by microfluidization. J. Control. Release 1990; 12: 223–233
   Web of Science ®Google Scholar
• Chow D., Karara A. Characterization, dissolution and bioavailability in rats of ibuprofen-b-cyclodextrin complex system. Int. J. Pharm. 1986; 28: 95–101
   Web of Science ®Google Scholar
• Couvreur P., Dubernet C., Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm., 41: 2–13
   Web of Science ®Google Scholar
• Eerikäinen H., Kauppinen E. I. Preparation of polymeric nanoparticles containing corticosteroid by a novel aerosol flow reactor method. Int. J. Pharm. 2003; 263: 69–83
   PubMed Web of Science ®Google Scholar
• Irie T., Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 1997; 86: 147–162
   PubMed Web of Science ®Google Scholar
• Jansen T., Xhonneux B., Mesens J., Borgers M. Beta-cyclodextrins as vehicles in eye-drop formulations: an evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxic. Res. 1990; 7: 459–468
   PubMedGoogle Scholar
• Jung S. W., Jeong Y. I., Kim S.H. Characterization of hydrophobized pullulan with various hyfrophobicities. Int. J. Pharm. 2003; 254: 109–121
   PubMed Web of Science ®Google Scholar
• Kahn C. R., Shechter Y. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. Goodman and Gilmann's The Pharmacological Basis of Therapeutics8th, A. G. Gilmann, T. W. Rall, A. S. Nies, P. Taylor. Pergamon Press, New York 1990; 1485–1486
   Google Scholar
• Khan K. A. The concept of dissolution efficiency. J. Pharm. Pharmacol. 1975; 27: 48–49
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy R., Wolka A. M., Shao Z., Mitra A. K. Cyclodextrins as mucosal absorption promotors. IV: Evaluation of nasal mucotoxicity. Eur. J. Pharm. Biopharm. 1995; 41: 296–301
   Web of Science ®Google Scholar
• Leroux J. C., Allémann E., Doelker E., Gurny R. New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur. J. Pharm. Biopharm. 1995; 41: 14–18
   Web of Science ®Google Scholar
• Leroy-Lechat F., Wouessidjewe D., Andreux J. P., Puisieux F., Duchêne D. Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives. Int. J. Pharm. 1994; 101: 97–103
   Web of Science ®Google Scholar
• Loftsson T., Brewster M. E. Pharmaceutical applications of cyclodextrins. I. Drug solubilisation and stabilization. J. Pharm. Sci. 1996; 85: 1012–1025
   PubMedGoogle Scholar
• Mesens J. L., Putteman P., Verheyen P. Pharmalogical application of 2-hydroxypropal-β-cyclodextrin. New Trends in Cyclodextrins and Derivatives, D. Duchêne. Editions de Santê, ParisFrance 1991; 369–407
   Google Scholar
• Moyano J. R., Arias-Blanco M. J., Gines J. M., Giordano F. Solid-state characterization and dissolution characteristics of gliclazide-β-cyclodextrin inclusion complexes. Int. J. Pharm. 1997a; 148: 211–217
   Web of Science ®Google Scholar
• Moyano J. R., Arias-Blanco M. J., Gines J. M., Rabasco A. M., Perez-Martinez J.I., Mor M., Giordano F. Nuclear magnetic resonance investigations of the inclusion complexation of gliclazide with beta-cyclodextrin. J Pharm Sci. 1997b; 86: 72–75
   PubMed Web of Science ®Google Scholar
• Müller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what can we expect for the future. Adv. Drug Deliv. Rev. 2001; 47: 3–19
   PubMed Web of Science ®Google Scholar
• Otagiri M., Imai T., Hirayama F., Uekama K., Yamasaki M. Inclusion complex formations of the anti-inflammatory drug flurbiprofen with cyclodextrins in aqueous solution and in solid state. Acta Pharm. Suec. 1983; 20: 11–20
   Google Scholar
• Özkan Y., Atay T., Dikmen N., Işimer A., Aboul-Enein H. Y. Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with beta-cyclodextrin. Pharm. Acta Helv. 2000; 74: 365–370
   PubMedGoogle Scholar
• Pignatello R., Ferro M., Puglisi G. Preparation of solid dispersions of nonsteroidal anti-inflammatory drugs with acrylic polymers and studies on mechanisms of drug-polymer interactions. AAPS Pharm. Sci. Tech. 2002; 3: E10
   PubMedGoogle Scholar
• Pitha J., Milecki J., Fales H., Pannell L., Uekama K. Hydroxypropyl-β- cyclodextrin: preparation and characterization; effects on solubility of drugs. Int. J. Pharm. 1986; 29: 73–82
   Web of Science ®Google Scholar
• Pitha J., Pitha J. Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients. J. Pharm. Sci. 1985; 74: 987–990
   PubMed Web of Science ®Google Scholar
• Redenti E., Peveri T., Zanol M., Ventura P., Gnappi G., Montenero A. A study on the differentiation between amorphous piroxicam: β-cyclodextrin complex and a mixture of the two amorphous components. Int. J. Pharm. 1996; 129: 289–294
   Web of Science ®Google Scholar
• Saenger W. Cyclodextrin inclusion compounds in research and laboratory. Angew. Chem. Int. Ed. Engl. 1980; 19: 344–362
   Web of Science ®Google Scholar
• Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem. Rev. 1998; 98: 1743–1753
   PubMed Web of Science ®Google Scholar
• Tessier D., Dawson K., Tetrault J. P., Bravo G., Meneilly G. S. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet. Med. 1994; 11: 974–980
   PubMed Web of Science ®Google Scholar
• Uekama K., Hirayama F., Irie T. Pharmaceutical uses of cyclodextrinderivatives. High Performance Biomaterials, A Comprehensive Guide to Medical and Pharmaceutical Applications, M. Szycher. Technomic, Lancaster 1991; 789–806
   Google Scholar
• Uekama K., Masaki K., Arimori K., Irie T., Hirayama F. Effects of beta- and dimethyl beta-cyclodextrins on release and percutaneous absorption behaviors of prednisolone from some ointment bases. Yakugaku Zasshi 1987; 107: 449–456
   PubMed Web of Science ®Google Scholar
• Winters C. S., York P., Timmins P. Solid state examination of a gliclazide: beta-cyclodextrin complex. Eur. J. Pharm. Sci. 1997; 5: 209–214
   Web of Science ®Google Scholar